Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2016

Jul 8, 2016

33651_dirs_2016-07-08_7926eaf9-e52a-4b89-adf6-cbc7f60f8733.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2016-07-01

Reporting Person: Nejadnik Bijan (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-07-01 Common Stock J 8503 $0.3995 Acquired 8503 Direct

Footnotes

F1: Pursuant to the Issuer's Employee Stock Purchase Plan